Through the pilot screening, we found HCC-specific drugs (methotrexate, pyrimethamine, and aminopterin, all anti-folate drugs) that significantly induced cell death in HCC (CHALV1+/AFP+) cells while minimizing the damage to hepatocytes (CHALV1−/AFP−) (Fig. 3b, Table 1). The gene discussed is AFP; the disease is hepatocellular carcinoma.